Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
Interventions
Intranasal ketamine
Drug
Lead sponsor
Abigail Nixon
Other
Eligibility
3 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
The Bronx, New York
Conditions
Critical Illness, Depressive Symptoms
Interventions
Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
Drug · Other
Lead sponsor
Hospital Italiano de Buenos Aires
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Pain
Interventions
Acetaminophen, Bupivacain, Saline
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obsessive Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional

Post-op Ketamine Study

NCT03865550
Conditions
Osteo Arthritis Knee
Interventions
Isotonic saline, Ketamine Injectable Solution
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
75 participants
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Conditions
Opioid-use Disorder, Pain, Acute
Interventions
HYDROmorphone Injectable Solution, Ketamine, Placebos
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Acute Ischemic Stroke
Interventions
Ketamine, Normal Saline, Midazolam injection
Drug · Other
Lead sponsor
Lower Merion Neurology Research Foundation
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Conditions
Depression, Anhedonia
Interventions
Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
Device · Behavioral · Drug
Lead sponsor
Erika Forbes
Other
Eligibility
15 Years to 25 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Phase 4 Interventional Results available

Ketamine for Pain in the Emergency Department

NCT03896230
Conditions
Acute Pain
Interventions
Ketamine Injectable Product
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hackensack, New Jersey